Intellia appoints Muna Bhanji as Class I director, expanding board to nine

Intellia Therapeutics, Inc.

Muna Bhanji appointed to newly created Class I director seat, board expands from 8 to 9 members.
Bhanji is founder of TIBA Global Access, former 30-year Merck senior VP for global market access & policy.
Received option for 11,700 shares at $50.29/exercise price and 7,954 RSUs, vesting over 3 years.
Term expires at 2023 annual meeting; Bhanji deemed independent under Nasdaq standards.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Muna Bhanji

Director

NTLA · Intellia Therapeutics, Inc.

Effective: 2022-04-28
Filed: May 3, 2022, 7:59 PM ET

On April 28, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Muna Bhanji, as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Muna Bhanji was appointed as Director at Intellia Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 28, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Muna Bhanji, as a Class I director

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-137551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.